Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» AnaptysBio
AnaptysBio
Catalysts ahead for the smaller players
Catalysts ahead for the smaller players
EP Vantage
89Bio
Altimmune
AnaptysBio
BioXcel Therapeutics
Calliditas Therapeutics
Eli Lilly
Esperion Therapeutics
Geron
Nektar Therapeutics
Oramed Pharmaceuticals
Pliant Therapeutics
Replimune
Selecta Biosciences
Swedish Orphan Biovitrum
Vera Therapeutics
Viking Therapeutics
Flag link:
AnaptysBio's HARP plays dud note, prompting rethink of imsidolimab strategy
AnaptysBio's HARP plays dud note, prompting rethink of imsidolimab strategy
Fierce Biotech
AnaptysBio
imsidolimab
hidradenitis suppurativa
Flag link:
Chasing AnaptysBio and Lilly, MiroBio rounds up $97M for autoimmune checkpoint agonist clinical trials
Chasing AnaptysBio and Lilly, MiroBio rounds up $97M for autoimmune checkpoint agonist clinical trials
Fierce Biotech
MiroBio
venture capital
autoimmune disease
Eli Lilly
AnaptysBio
Medicxi
OrbiMed
Flag link:
AnaptysBio CEO Exits After Decade in the Role
AnaptysBio CEO Exits After Decade in the Role
BioSpace
AnaptysBio
Hamza Suria
Pharma CEOs
Flag link:
The biotech behind GlaxoSmithKline's PD-1 just scored a $250M cash deal for royalties
The biotech behind GlaxoSmithKline's PD-1 just scored a $250M cash deal for royalties
Endpoints
AnaptysBio
Jemperli
GSK
Flag link:
AnaptysBio gets double downgrade at JPM after Imsidolimab trial failure
AnaptysBio gets double downgrade at JPM after Imsidolimab trial failure
Seeking Alpha
AnaptysBio
imsidolimab
clinical trials
palmoplantar pustulosis
Flag link:
With FDA decision looming, GSK sweetens the PD-1 pot for discovery partner AnaptysBio as Hal Barron moves to guard his oncology strategy
With FDA decision looming, GSK sweetens the PD-1 pot for discovery partner AnaptysBio as Hal Barron moves to guard his oncology strategy
Endpoints
AnaptysBio
GSK
Tesaro
Zejula
Flag link:
AnaptysBio's etokimab provides more disappointing results, raising questions about compound's future
AnaptysBio's etokimab provides more disappointing results, raising questions about compound's future
Endpoints
AnaptysBio
rhinosinusitis
etokimab
clinical trials
nasal polyps
Flag link:
Here's Why AnaptysBio Rose 22.1% in May
Here's Why AnaptysBio Rose 22.1% in May
Motley Fool
AnaptysBio
Flag link:
Why AnaptysBio, bluebird bio, and Exelixis Shares Rebounded Last Friday
Why AnaptysBio, bluebird bio, and Exelixis Shares Rebounded Last Friday
Motley Fool
pharma stocks
AnaptysBio
Bluebird Bio
Exelixis
COVID-19
Flag link:
Top 7 Companies in Biotech Beach by Revenue
Top 7 Companies in Biotech Beach by Revenue
BioSpace
Biotech Beach
San Diego
California
Amgen
Neurocrine
Acadia Pharmaceuticals
Retrophin
Tocagen
Mirati Therapeutics
AnaptysBio
Flag link:
Stanford researchers pursue AnaptysBio's embattled IL-33 drug in peanut allergy
Stanford researchers pursue AnaptysBio's embattled IL-33 drug in peanut allergy
Fierce Biotech
Stanford University
AnaptysBio
peanut allergy
etokimab
Flag link:
AnaptysBio shares collapse after 'worst case scenario' for key drug
AnaptysBio shares collapse after 'worst case scenario' for key drug
Biopharma Dive
AnaptysBio
etokimab
clinical trials
Flag link:
AnaptysBio Prepares for a Potential Gear Shift
AnaptysBio Prepares for a Potential Gear Shift
Yahoo/Motley Fool
AnaptysBio
earnings
etokimab
Flag link:
The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate
The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate
Yahoo/Benzinga
biotech
earnings
Immunic
Alkermes
Conatus
Aevi Genomic
Tricida
Curis
Ultragenyx
Leap Therapeutics
Cidara Therapeutics
Akcea
Spark Therapeutics
Eli Lilly
AnaptysBio
clinical trials
Flag link:
Rivals’ disappointing results in asthma trial drag down shares of Anaptys Bio
Rivals’ disappointing results in asthma trial drag down shares of Anaptys Bio
Stat
Sanofi
Regeneron
IL-33
asthma
monoclonal antibodies
REGN3500
AnaptysBio
Dupixent
Flag link:
AnaptysBio Inc.'s Lead Candidate Gets New Priorities -- The Motley Fool
AnaptysBio Inc.'s Lead Candidate Gets New Priorities -- The Motley Fool
Motley Fool
AnaptysBio
earnings
peanut allergy
Flag link:
AnaptysBio plans phase 2b peanut allergy trial after taking positives from POC data
AnaptysBio plans phase 2b peanut allergy trial after taking positives from POC data
Fierce Biotech
AnaptysBio
clinical trials
peanut allergy
ANB020
Flag link:
2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing?
2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing?
Motley Fool
biotech
BeiGene
China
Celgene
AnaptysBio
ANB020
eczema
Flag link:
4 Biotechs Ready to Kill the Market in 2018
4 Biotechs Ready to Kill the Market in 2018
BIospace
biotech
Acadia
Sangamo Therapeutics
AnaptysBio
Sino Biopharmaceutical
Flag link:
Pages
1
2
next ›
last »